Net Sales Milestone Events Sample Clauses

Net Sales Milestone Events. First calendar year in which aggregate Net Sales of all Products in the U.S., Canada and Mexico exceed $100 million $5,000,000
View SourceView Similar (2)
Net Sales Milestone Events. First calendar year in which aggregate annual Net Sales of Products exceeds [***] [***] First calendar year in which aggregate annual Net Sales of Products exceeds [***] [***] First calendar year in which aggregate annual Net Sales of Products exceeds [***] [***] First calendar year in which aggregate annual Net Sales of Products exceeds [***] [***]
View Source
Net Sales Milestone Events. First Calendar Year in which the sum of (i) aggregate Net Sales of the ONC-201 Products in the O▇▇-▇▇▇ ▇▇▇▇▇▇▇▇▇ in such Calendar Year and (ii) aggregate Net Sales of the ONC-206 Products in the O▇▇-▇▇▇ ▇▇▇▇▇▇▇▇▇ in such Calendar Year equals or exceeds $[***] $[***] First Calendar Year in which the sum of (i) aggregate Net Sales of the ONC-201 Products in the O▇▇-▇▇▇ ▇▇▇▇▇▇▇▇▇ in such Calendar Year and (ii) aggregate Net Sales of the ONC-206 Products in the O▇▇-▇▇▇ ▇▇▇▇▇▇▇▇▇ in such Calendar Year equals or exceeds $[***] $[***] First Calendar Year in which the sum of (i) aggregate Net Sales of the ONC-201 Products in the O▇▇-▇▇▇ ▇▇▇▇▇▇▇▇▇ in such Calendar Year and (ii) aggregate Net Sales of the ONC-206 Products in the O▇▇-▇▇▇ ▇▇▇▇▇▇▇▇▇ in such Calendar Year equals or exceeds $[***] $[***] First Calendar Year in which the sum of (i) aggregate Net Sales of the ONC-201 Products in the O▇▇-▇▇▇ ▇▇▇▇▇▇▇▇▇ in such Calendar Year and (ii) aggregate Net Sales of the ONC-206 Products in the O▇▇-▇▇▇ ▇▇▇▇▇▇▇▇▇ in such Calendar Year equals or exceeds $[***] $[***]
View Source
Net Sales Milestone Events. (A) Worldwide annual Net Sales in any Calendar Year equal to or greater than [***] but less than [***] [***] (B) Worldwide annual Net Sales in any Calendar Year equal to or greater than [***] but less than [***] [***] (C) Worldwide annual Net Sales in any Calendar Year equal to or greater than [***] [***] Each of the Milestone Payments shall be payable one (1) time only. For the avoidance of doubt, (x) each of the Milestone Payments shall become payable upon the occurrence of the associated Milestone Event, irrespective of the order in which the Milestone Events occur relative to each other, and (y) no amounts shall be due for subsequent or repeated achievements by a Product of any Milestone Event. If Purchaser skips a milestone event listed in the above Sections 1.05(i)(A)-(B) or 1.05(ii)(A)-(B), then Purchaser shall pay the amounts set forth in the skipped milestone upon achieving a subsequent milestone event, in addition to the amounts payable for such subsequent milestone event. In accordance with the foregoing, the maximum total cash Milestone Payments payable by Purchaser to Seller and Seller Representative’s designee under this Agreement would be Sixty Four Million Five Hundred Thousand Dollars ($64,500,000) and the maximum number of Purchaser Common Shares payable as Milestone Payments by Purchaser to Seller’s equityholders under this Agreement would be Eight Hundred Thirty Six Thousand Five Hundred Thirteen (836,513) shares. Any issuance of Purchaser Common Shares under this Section 1.05 shall be in accordance with and pursuant to the Share Purchase Agreement.
View Source

Related to Net Sales Milestone Events

  • Milestone Event Milestone Payment [***] [***]

  • Sales Milestones On a Co-Co Product-by-Co-Co Product basis, Celgene shall make the following sales milestone payments to Jounce that are set forth below upon the first achievement by or on behalf of Celgene, its Affiliates or Sublicensees of the Sales Milestone Events set forth below with respect to sales of such Co-Co Product in the ROW Territory. [***] [***] [***] [***]

  • Sales Milestone Payments Artiva shall make the following one-time, non-refundable and non-creditable sales milestone payments to GCLC when the aggregate annual Net Sales of Products in the Territory first reach the thresholds specified below. Artiva shall notify GCLC promptly of the achievement of each such sales threshold. Each sales milestone payment shall be made by Artiva within [***] days after the end of the calendar quarter in which such sales threshold is achieved. To the extent more than one sales threshold is reached in any given calendar year, then the applicable milestone payment for each such achievement shall be due and owing with respect to such calendar year. For clarification, the total milestone payments payable hereunder if all milestone events are achieved is [***].

  • Development Milestone Payments TriSalus shall pay (or cause to be paid) to Dynavax, in accordance with and subject to the terms of this Section 2.3, Section 2.4 and Section 6.4 (each such milestone, a “Development Milestone”, and each payment in respect thereof, a “Development Milestone Payment”): (i) Upon the successful completion by a Milestone Obligor after the Closing of a [**] study with respect to a Product using PEDD, a payment of [**] US Dollars ($[**]), with such Development Milestone Payment being payable only once (for purposes of the foregoing, successful completion means completion of such study in accordance with the plan for such study); (ii) For the first patient Dosed by a Milestone Obligor in each Phase 1 Clinical Trial for a Product for each Indication, a payment of [**] US Dollars ($[**]), up to a maximum of [**] such payments, regardless of how many Indications are pursued for a Product or how many Products are in development by Milestone Obligor; (iii) For the first patient Dosed by a Milestone Obligor in each Phase 2 Clinical Trial for a Product for each Indication, a payment of [**] US Dollars ($[**]), up to a maximum of [**] such payments regardless of how many Indications are pursued for a Product or how many Products are in development by Milestone Obligor; (iv) For each Phase 2 Clinical Trial for a Product for each Indication conducted by or on behalf of a Milestone Obligor meeting the primary endpoint for such Phase 2 Clinical Trial based on full tables, figures and listings or continued development of such Product for the same Indication as such Phase 2 Clinical Trial, a payment of [**] US Dollars ($[**]), up to a maximum of [**] such payments, regardless of how many Indications are pursued for a Product or how many Products are in development by Milestone Obligor; (v) For each Phase 3 Clinical Trial for a Product for each Indication conducted by or on behalf of a Milestone Obligor meeting the primary endpoint for such Phase 3 Clinical Trial based on full tables, figures and listings or continued development of such Product for the same Indication as such Phase 3 Clinical Trial, a payment of [**] US Dollars ($[**]), up to a maximum of [**] such payments, regardless of how many Indications are pursued for a Product or how many Products are in development by Milestone Obligor; (vi) Upon receipt by a Milestone Obligor of each Regulatory Approval for any Product for any Indication in the U.S., a payment of [**] US Dollars ($[**]), up to a maximum of [**] such payments, regardless of how many Indications are pursued for a Product or how many Products achieve Regulatory Approval; (vii) Upon receipt by a Milestone Obligor for each Regulatory Approval of any Product for any Indication in any country or region outside the U.S., a payment of [**] US Dollars ($[**]), up to a maximum of [**] such payments, regardless of how many Indications are pursued for a Product or how many Products achieve Regulatory Approval; (viii) Upon receipt by a Milestone Obligor for each Regulatory Approval for a Product with Orphan Drug Exclusivity for each Indication of a Product in the U.S., a payment of [**] US Dollars ($[**]), up to a maximum of [**] such payments (which, for clarity, shall be payable in addition to the Development Milestone payable under Section 2.3(a)(vi) for receipt of such Regulatory Approval), regardless of how many Indications are pursued for a Product or how many Products achieve Regulatory Approval; and (ix) Upon receipt by a Milestone Obligor for each Regulatory Approval for a Product with Orphan Drug Exclusivity for each Indication of a Product in any country or region outside the U.S., a payment of [**] US Dollars ($[**]), up to a maximum of [**] such payments (which, for clarity, shall be payable in addition to the Development Milestone payable under Section 2.3(a)(vii) for receipt of such Regulatory Approval), regardless ​ of how many Indications are pursued for a Product or how many Products achieve Regulatory Approval.

  • Development Milestones In addition to its obligations under Paragraph 7.1, LICENSEE specifically commits to achieving (either itself or through the acts of a SUBLICENSEE) the following development milestones in its diligence activities under this AGREEMENT: (a) (b).